Peca Labs, Inc. — SEC Form D Filing

Peca Labs, Inc. filed an SEC Form D on October 9, 2026, reporting $12.79M raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
October 9, 2026
Amount reported
$12.79M
Round stage
Seed
Industry
Medical Devices
Website
https://www.pecalabs.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Existing cardiovascular implantable devices, such as heart valves and vascular grafts, face problems with longevity, performance, and issues like thrombosis and hyperplasia.

Solution

Peca Labs develops polymeric cardiovascular implantable devices, including vascular grafts and heart valves, designed for better longevity, performance, and to reduce complications like thrombosis and hyperplasia.

Why now

Advances in polymer science and materials engineering now enable the creation of highly durable, biocompatible, and customizable implantable medical devices. There's also a growing recognition of the need for improved solutions for congenital heart defects and long-term cardiovascular health.

Verdict

Investors committed here because the deep, persistent problems with existing cardiovascular implants created an undeniable market need, not because Peca Labs had demonstrated scalable clinical traction. The implicit bet was on materials science innovation overcoming decades of incremental device improvements, translating into superior long-term patient outcomes and a significantly extended product lifespan. This upside was inherently limited by the extremely high regulatory bar for implantable devices, the long sales cycle into established hospital systems, and the capital-intensive nature of medical device development that mandates further dilutive rounds.

Source: SEC EDGAR Form D filing